TORONTO, ON--(Marketwired - July 29, 2015) - ViaCyte, Inc. announced the opening of a second site in its Phase 1/2 trial called STEP ONE, or Safety, Tolerability and Efficacy of VC-01™ Combination ...
Back in the summer of 2014, J&J ($JNJ) invested $20 million into San Diego-based ViaCyte, picking up an option to acquire its lead therapy for Type 1 diabetes just as ...
NEW YORK, Dec. 13, 2011 /PRNewswire-USNewswire/ -- JDRF announced today its support of a pioneering diabetes research program that is developing a first-of-its-kind cell therapy for type 1 diabetes ...
ViaCyte, Inc., a clinical stage regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a materials science company with expertise in medical device and drug delivery technologies, ...
SAN DIEGO, July 10, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem ...
SAN DIEGO, April 17, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced the recent issuance of more than 200 patents, which provide protection to the ...
SAN DIEGO and NEWARK, Del., March 29, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, and W. L. Gore & Associates, Inc. ("Gore"), a global materials science company ...
ViaCyte and Janssen Biotech have entered Phase I/Phase II clinical trials for VC-01, a candidate treatment for the treatment of type 1 diabetes. ViaCyte a privately held regenerative medicine company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results